Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Organic and Inorganic Nanoparticles for Prevention and Diagnosis of Gastric Cancer
Departamento de Ciencias y Tecnología Farmacéuticas, Universidad de Chile, Santiago.
Advancer Center for Chronic Diseases (ACCDiS), Santiago.
Advancer Center for Chronic Diseases (ACCDiS), Santiago.
Luleå University of Technology, Department of Health Sciences, Medical Science. Departamento de Ciencias y Tecnología Farmacéuticas, Universidad de Chile, Santiago.
Show others and affiliations
2015 (English)In: Current pharmaceutical design, ISSN 1381-6128, E-ISSN 1873-4286, Vol. 21, no 29, 4145-4154 p.Article in journal (Refereed) Published
Abstract [en]

Organic and inorganic nanoparticles show great potential for cancer diagnosis and treatment. Because gastric cancer (GC) represents the second most deadly type of neoplasia worldwide, continued research efforts by scientists and clinicians are essential to improve diagnosis and treatment. This paper reviews significant findings in the area of nanoparticles (organic and inorganic origin) that may aid in prevention and diagnosis of GC. This review focuses in the first section on H. pylori and the connection to GC, highlighting nanoformulations designed to control bacterial growth. The second section evaluates the potential of different imaging techniques (especially using inorganic nanoparticles) in the detection of GC, and the third section summarizes how nanotechnology may be employed in the analytical detection of GC biomarkers (metallic plasmons, electrochemical biosensors and colorimetric sensors). We foresee that the prevention and diagnosis of GC will require the development of complex collaborative studies. Additionally, scientists also need to be tightly connected to industry in order to facilitate upscaling and rapid transfer of promising products to the clinic.

Place, publisher, year, edition, pages
2015. Vol. 21, no 29, 4145-4154 p.
National Category
Pharmaceutical Sciences Other Health Sciences
Research subject
Health Science
Identifiers
URN: urn:nbn:se:ltu:diva-64678PubMedID: 26323433Scopus ID: 2-s2.0-84945903166OAI: oai:DiVA.org:ltu-64678DiVA: diva2:1118588
Available from: 2017-06-30 Created: 2017-06-30 Last updated: 2017-07-06Bibliographically approved

Open Access in DiVA

No full text

PubMedScopus

Search in DiVA

By author/editor
Morales, Javier O.
By organisation
Medical Science
In the same journal
Current pharmaceutical design
Pharmaceutical SciencesOther Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 6 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf